We consider the relationship between the target affinity of a monoclonal antibody and its in vivo potency. The dynamics of the system is described mathematically by a target-mediated drug disposition model. As a measure of potency, we consider the minimum level of the free receptor following a single bolus injection of the ligand into the plasma compartment. From the differential equations, we derive two expressions for this minimum level in terms of the parameters of the problem, one of which is valid over the full range of values of the equilibrium dissociation constant K(D) and the other which is valid only for a large drug dose or for a small value of K(D). Both of these formulae show that the potency achieved by increasing the associat...
Bispecific antibodies (BsAb) bind to two different targets, and create two binary and one ternary co...
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most ...
La pharmacocinétique (PK) des anticorps monoclonaux (mAbs) est sujette à d’importantes variations in...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
An extended pharmacokinetic/pharmacodynamic (PK/PD) model is presented, in which the effect of bindi...
For monoclonal antibody (mAb) drugs with soluble targets (e.g. cytokines and growth factors), targ...
Biopharmaceuticals, especially monoclonal antibodies, have been increasingly used to treat several c...
International audienceThe interaction between ligands and receptors is often described in terms of 5...
We consider the possibility of free receptor (antigen/cytokine) levels rebounding to higher than the...
The interest in therapeutic monoclonal antibodies (mAbs) has continuously growing in several disease...
ABSTRACTReceptor occupancy assays applied in clinical studies provide insights into pharmacokinetic-...
Triggering of the T cell receptor (TCR) may be antagonized by ligands that are slight variants of th...
Abstract. In this paper we discuss two models involving protein binding. The first model describes a...
Abstract: It has been known that devising a suitable pharmacokinetic equation in ADC(Antibody Drug C...
Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interd...
Bispecific antibodies (BsAb) bind to two different targets, and create two binary and one ternary co...
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most ...
La pharmacocinétique (PK) des anticorps monoclonaux (mAbs) est sujette à d’importantes variations in...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
An extended pharmacokinetic/pharmacodynamic (PK/PD) model is presented, in which the effect of bindi...
For monoclonal antibody (mAb) drugs with soluble targets (e.g. cytokines and growth factors), targ...
Biopharmaceuticals, especially monoclonal antibodies, have been increasingly used to treat several c...
International audienceThe interaction between ligands and receptors is often described in terms of 5...
We consider the possibility of free receptor (antigen/cytokine) levels rebounding to higher than the...
The interest in therapeutic monoclonal antibodies (mAbs) has continuously growing in several disease...
ABSTRACTReceptor occupancy assays applied in clinical studies provide insights into pharmacokinetic-...
Triggering of the T cell receptor (TCR) may be antagonized by ligands that are slight variants of th...
Abstract. In this paper we discuss two models involving protein binding. The first model describes a...
Abstract: It has been known that devising a suitable pharmacokinetic equation in ADC(Antibody Drug C...
Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interd...
Bispecific antibodies (BsAb) bind to two different targets, and create two binary and one ternary co...
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most ...
La pharmacocinétique (PK) des anticorps monoclonaux (mAbs) est sujette à d’importantes variations in...